Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer
Hiro‐omi Kanayama, K Yokota, Yasushi Kurokawa, Yu Murakami, Masaaki Nishitani, Shunsuke Kagawa
Abstract
Hiro‐omi Kanayama, K Yokota, Yasushi Kurokawa, Yu Murakami, Masaaki Nishitani, Shunsuke Kagawa
Abstract
No AccessJournal of UrologyUrological Survey: Abstracts: Principles of Oncology and Immunology, and Tumors of Bladder, Penis and Urethra1 Nov 1998Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer H. Kanayama, K. Yokota, Y. Kurokawa, Y. Murakami, M. Nishitani, and S. Kagawa H. KanayamaH. Kanayama , K. YokotaK. Yokota , Y. KurokawaY. Kurokawa , Y. MurakamiY. Murakami , M. NishitaniM. Nishitani , and S. KagawaS. Kagawa View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62449-2AboutFull TextPDF Cite Export CitationSelect Citation formatNLMIEEEACMAPAChicagoMLAHarvardTips on citation downloadDownload citationCopy citation ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer." The Journal of Urology, 160(5), pp. 1931–1932 Department of Urology, School of Medicine, University of Tokushima, Tokushima, Japan© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 160Issue 5November 1998Page: 1931-1932 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.Metrics Author Information H. Kanayama More articles by this author K. Yokota More articles by this author Y. Kurokawa More articles by this author Y. Murakami More articles by this author M. Nishitani More articles by this author S. Kagawa More articles by this author Expand All Advertisement PDF downloadLoading ...
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
No AccessJournal of UrologyUrological Survey: Abstracts: Principles of Oncology and Immunology, and Tumors of Bladder, Penis and Urethra1 Nov 1998Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer H. Kanayama, K. Yokota, Y. Kurokawa, Y. Murakami, M. Nishitani, and S. Kagawa H. KanayamaH. Kanayama , K. YokotaK. Yokota , Y. KurokawaY. Kurokawa , Y. MurakamiY. Murakami , M. NishitaniM. Nishitani , and S. KagawaS. Kagawa View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62449-2AboutFull TextPDF Cite Export CitationSelect Citation formatNLMIEEEACMAPAChicagoMLAHarvardTips on citation downloadDownload citationCopy citation ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer." The Journal of Urology, 160(5), pp. 1931–1932 Department of Urology, School of Medicine, University of Tokushima, Tokushima, Japan© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 160Issue 5November 1998Page: 1931-1932 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.Metrics Author Information H. Kanayama More articles by this author K. Yokota More articles by this author Y. Kurokawa More articles by this author Y. Murakami More articles by this author M. Nishitani More articles by this author S. Kagawa More articles by this author Expand All Advertisement PDF downloadLoading ...
Key concepts: Matrix metalloproteinase, Tissue inhibitor of metalloproteinase, Bladder cancer, Matrix metalloproteinase 9, Metalloproteinase, Cancer research, Matrix metalloproteinase inhibitor, Medicine